The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2024

Filed:

Feb. 27, 2019
Applicant:

Oslo Universitetssykehus Hf, Oslo, NO;

Inventors:

Gustav Gaudernack, Sandvika, NO;

Gunnar Kvalheim, Oslo, NO;

Else Marit Inderberg, Oslo, NO;

Sébastien Wälchli, Oslo, NO;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); C12N 5/0636 (2013.01); C07K 2319/03 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01);
Abstract

The present invention provides a nucleic acid molecule encoding a specific binding molecule capable of binding an h TERT peptide comprising the amino acid sequence set forth in SEQ ID NO: 1 when the peptide is presented by a Class II Major Histocompatibility Complex (MHC), wherein the specific binding molecule comprises a first polypeptide comprising a variable region of an α-chain and a second polypeptide comprising a variable region of a β-chain of a T-cell receptor (TCR), and wherein: (a) the variable region of an α-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the amino acid sequences set forth in SEQ ID NOs: 2, 3 and 4; and (b) the variable region of a β-chain comprises CDR sequences CDR1, CDR2 and CDR3 which respectively comprise the sequences set forth in SEQ ID NOs: 5, 6 and 7. Recombinant constructs, vectors and host cells comprising such nucleic acid molecules are also provided, as are specific binding molecules encoded by such nucleic acid molecules. The present invention has utility in the treatment of cancer.


Find Patent Forward Citations

Loading…